Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | TEK | Q02763 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544134 | 1.00 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21942686 | 0.87 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23469011 | 0.86 | PIK3CD (0.45) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21127668 | 0.83 | PI4KA (0.42) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21872517 | 0.83 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21943146 | 0.83 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21539238 | 0.83 | PI4KB (0.41) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL24971532 | 0.81 | DHFR (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21078676 | 0.80 | SLC2A1 (0.49) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12946398 | 0.79 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-23 | — | — | US | disclosed |
| US-12031179-B2 | Methods and compositions for reducing nucleotide impurities | Singular Genomics Systems, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12031179-B2 | Methods and compositions for reducing nucleotide impurities | Singular Genomics Systems, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-01-18 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
| US-7339054-B2 | Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates | MERCK & CO., INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | MERCK SHARP & DOHME CORP. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA1 446/4885ADORA2B 827/4885 |
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | BLVRB, BCDIN3D, FOSB | ADORA2A 3304/4885ADORA1 3504/4885ADORA2B 954/4885 |
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | ADORA2A 263/4885ADORA1 340/4885ADORA2B 579/4885 |
| US-20240016820-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | ADORA2A 875/4885ADORA1 1043/4885ADORA2B 1078/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | ADORA2A 174/4885ADORA1 283/4885ADORA2B 368/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA2A 368/4885ADORA1 344/4885ADORA2B 686/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | ADORA2A 186/4885ADORA1 249/4885ADORA2B 474/4885 |
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | ADORA2A 2428/4885ADORA1 865/4885ADORA2B 955/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | ADORA2A 116/4885ADORA1 295/4885ADORA2B 412/4885 |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | DUT, RNGTT, DPYD | ADORA2A 81/4885ADORA1 220/4885ADORA2B 232/4885 |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | ABCG2, ABCB1, ARSA | ADORA2A 2723/4885ADORA1 3920/4885ADORA2B 2137/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | ADORA2A 195/4885ADORA1 343/4885ADORA2B 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.